

**Valuation Report for the purpose of Regulation 164 and 166A ICDR
for Preferential Issue of equity shares of**

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad, Gujarat, India, 380055

Email: dharachem99@yahoo.in

Prepared by

MANISH SANTOSH BUCHASIA

IBBI REGISTERED VALUER

Assets class: Securities or financial assets

RV Reg. no: IBBI/RV/03/2019/12235

306, "GALA MART" Nr SOBO CENTRE, SOUTH BOPAL, Ahmedabad -380058, Gujarat
Land Line 912717480025, Office Mobile 9327916394 www.buchasia.com cs@buchasia.co



To,

The Board of Directors,

DIPNA PHARMACHEM LIMITED


A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat,
India, 380055

Ref: Independent Fair Valuation of DIPNA PHARMACHEM LIMITED (“DPL” or “Company”) as on relevant date i.e., 5th March, 2025 as per SEBI (ICDR) Regulations for the purpose of Preferential Issue of equity shares.

We have been engaged by DIPNA PHARMACHEM LIMITED (“DPL” or “Company”) for the purpose of assessing fair value of equity shares as of the relevant date i.e. 05th March, 2025 of the Company, a company registered under the Companies Act, 1956.

The underlying transaction is the preferential issue of shares of Company to certain investors. The Company is frequently traded company listed on BSE In terms of Regulation 166A read with Regulation 164 of SEBI (Issue of Capital & Disclosure Requirements) Regulations, 2018, a preferential issue, which may result in a change in control or allotment of more than 5 % of the post issue fully diluted share capital of an issuer, to an allottee or to allottees acting in concert, shall require a valuation report from an independent registered valuer and should be considered for determining the issue price.


Based on the information provided by the management, I, MANISH SANTOSH BUCHASIA, Registered Valuer (Regn no: IBBI/RV/03/2019/12235), hereby certify that I have arrived at the “Fair Value” (“Valuation” or “Value”) of the Company as at the relevant date i.e. 05th March, 2025. Based on our assessment, the Value of the shares of the company should be **INR 13.02 (Thirteen rupees two paise only) per share**. The computation of Fair value of the Company has been attached as Annexure.


RV MANISH SANTOSH BUCHASIA
IBBI REGISTERED VALUER

Assets class: Securities or financial assets

RV Reg. no: IBBI/RV/03/2019/12235;

Date: 05/03/2025



“CONTENT”

Sr. No.	Particulars
1	Executive Summary
2	Background information
3	Purpose of valuation and appointing authority
4	Identity of the valuer
5	Disclosure of valuer interest or conflict
6	Date of appointment, valuation date and date of report
7	Inspections and/or investigations undertaken
8	Nature and sources of the information used or relied upon
9	Restrictions on use of the report
10	Caveats, limitations and disclaimers
11	Valuation: Procedures and factors
12	Valuation Analysis
13	Calculation
14	Annexures



1. EXECUTIVE SUMMARY

DIPNA PHARMACHEM LIMITED (“company”) is a public limited company registered under the provisions of the Companies Act, 1956.

The company has engaged us to provide an Independent fair valuation of the shares of DIPNA PHARMACHEM LIMITED as per Regulations 164 and/or 165 (as applicable) of the SEBI (Issue of Capital & Disclosure Requirements) Regulations, 2018 (“ICDR”).

Accordingly, the valuation of the Equity Shares of the Company is arrived at basis higher of the following:

- a. the 90 trading days of the volume weighted average price of the related equity shares quoted on the recognised stock exchange preceding the relevant date i.e. from 25th October, 2024 to 04th March, 2025; or
- b. the 10 trading days of the volume weighted average prices of the related equity shares quoted on a recognised stock exchange preceding the relevant date i.e. from 18th February, 2025 to 04th March, 2025.

The above is based on data available on the BSE, being the recognised stock exchange in which the highest trading volume in respect of the equity shares of the issuer has been recorded during the preceding 90 trading days prior to the relevant date. The standard of value used in our valuation of Equity Share of the Company is **in accordance with Regulation 164 of the ICDR.**

Based on our analysis of the company and subject to our comments and caveats as further detailed in this report, we have arrived at the “Independent Fair Value” of the equity shares of the Company.

2. BACKGROUND INFORMATION

DIPNA PHARMACHEM LIMITED was incorporated on 19/07/2011 with the Registrar of Companies, Ahmedabad. The Corporate Identification Number of the Company is L24100GJ2011PLC066400 and registered office is situated at A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055.

Stock Price Information:

ISIN: INE0MC401013

CIN: L24100GJ2011PLC066400

BSE: DPL | 543594



Trading information: Frequently traded (Annexure “B”) volume weighted average price of 90 trading days and 10 trading days "BSE".

The Board of Directors of the Company is as follows

DIN/DPIN/PAN	Full Name	Designation	Date of Appointment
02507462	DIPNA KEYUR SHAH	Director	19/07/2011
03167258	KEYUR DIPAKKUMAR SHAH	Managing Director	01/05/2022
09565657	NANDISH SHAILESHBHAI JANI	Director	07/09/2022
08317653	NIRAV M SONI	Additional Director	11/10/2024

3. PURPOSE OF VALUATION AND APPOINTING AUTHORITY:

Based on the discussions held with the management and Key Managerial Personnel (KMP's), company is proposing Preferential Issue of equity shares. The Equity shares of the company are listed on BSE Limited and are frequently traded. In terms of Regulation 166A read with Regulation 164 of SEBI (Issue of Capital & Disclosure Requirements) Regulations, 2018 ('SEBI (ICDR) Regulations'), a preferential issue, which result in a allotment of more than 5 % of the post issue fully diluted share capital of an issuer, to an allottee or to allottees acting in concert, shall, besides the market price, requires valuation from an independent registered valuer and should be considered for determining the issue price. Thus, we, being Registered Valuers, have been appointed as per the appointment letter dated 24/02/2025. We are issuing this certificate for the purpose of compliance with the Chapter V of SEBI (ICDR) Regulations.

The company is looking to assess its Independent fair value of equity shares in accordance with Regulations 164 and/or 165 (as applicable) of the ICDR.

Since Regulation 164 deals with frequently traded shares and corresponding regulation 165 deals with infrequently traded shares, we have assessed them together based on the circumstances given in this case.

The relevant extract of the rules 164 and 165 are as under:

Pricing of Frequently traded shares

164. (1) *If the equity shares of the issuer have been listed on a recognised stock exchange for a period of 90 trading days or more as on the relevant date, the price of the equity shares to be allotted pursuant to the preferential issue shall be not less than higher of the following:*



a) the 90 trading days volume weighted average price of the related equity shares quoted on the recognised stock exchange preceding the relevant date; or

b) The 10 trading day's volume weighted average prices of the related equity shares quoted on a recognised stock exchange preceding the relevant date.

(2) If the equity shares of the issuer have been listed on a recognised stock exchange for a period of less than 90 trading days as on the relevant date, the price of the equity shares to be allotted pursuant to the preferential issue shall be not less than the higher of the following:

a) the price at which equity shares were issued by the issuer in its initial public offer or the value per share arrived at in a scheme of compromise, arrangement and amalgamation under sections 230 to 234 the Companies Act, 2013, as applicable, pursuant to which the equity shares of the issuer were listed, as the case may be; or

b) the average of the volume weighted average prices of the related equity shares quoted on the recognised stock exchange during the period the equity shares have been listed preceding the relevant date; or

c) the average of the 10 trading days volume weighted average prices of the related equity shares quoted on a recognised stock exchange preceding the relevant date.

(3) Where the price of the equity shares is determined in terms of sub-regulation (2), such price shall be recomputed by the issuer on completion of 90 trading days from the date of listing on a recognised stock exchange with reference to the 90 trading days volume weighted average prices of the related equity shares quoted on the recognised stock exchange during these 90 trading days and if such recomputed price is higher than the price paid on allotment, the difference shall be paid by the allottees to the issuer.

(4) A preferential issue of specified securities to qualified institutional buyers, not exceeding five in number, shall be made at a price not less than the 10 trading days volume weighted average prices of the related equity shares quoted on a recognised stock exchange preceding the relevant date.

(5) For the purpose of this Chapter, "frequently traded shares" means the shares of the issuer, in which the traded turnover on any recognised stock exchange during the 240 trading days preceding the relevant date is at least ten per cent of the total number of shares of such class of shares of the issuer:

Provided that where the share capital of a particular class of shares of the issuer is not identical throughout such period, the weighted average number of total shares of such class of the issuer shall represent the total number of shares.



Explanation: For the purpose of this regulation, 'stock exchange' means any of the recognised stock exchange(s) in which the equity shares of the issuer are listed and in which the highest trading volume in respect of the equity shares of the issuer has been recorded during the preceding 90 trading days prior to the relevant date.

Pricing of Infrequently traded shares

165. *Where the shares of an issuer are not frequently traded, the price determined by the issuer shall take into account the valuation parameters including book value, comparable trading multiples, and such other parameters as are customary for valuation of shares of such companies:*

Provided that the issuer shall submit a certificate stating that the issuer is in compliance of this regulation, obtained from an independent Registered valuer to the stock exchange where the equity shares of the issuer are listed.

Other conditions for pricing

166A. *(1) Any preferential issue, which may result in a change in control or allotment of more than five percent of the post issue fully diluted share capital of the issuer, to an allottee or to allottees acting in concert, shall require a valuation report from an independent registered valuer and consider the same for determining the price:*

Provided that the floor price, in such cases, shall be higher of the floor price determined under sub-regulation (1), (2) or (4) of regulation 164, as the case may be, or the price determined under the valuation report from the independent registered valuer or the price determined in accordance with the provisions of the Articles of Association of the issuer, if applicable:

Provided further that if any proposed preferential issue is likely to result in a change in control of the issuer, the valuation report from the registered valuer shall also cover guidance on control premium, which shall be computed over and above the price determined in terms of the first proviso:

Provided further that the valuation report from the registered valuer shall be published on the website of the issuer and a reference of the same shall be made in the notice calling the general meeting of shareholders.

(2) Any preferential issue, which may result in a change in control of the issuer, shall only be made pursuant to a reasoned recommendation from a committee of independent directors of the issuer after considering all the aspects relating to the preferential issue including pricing, and the voting pattern of the said committee's meeting shall be disclosed in the notice calling the general meeting of shareholders.



4. IDENTITY OF THE VALUER AND ANY OTHER EXPERTS INVOLVED IN THE VALUATION:

- RV Manish Santosh Buchasia
- IBBI Registered Valuer Assets class: Securities or financial assets
- RV Reg. no: IBBI/RV/03/2019/12235.

5. DISCLOSURE OF VALUER INTEREST/INTEREST CONFLICT (IF ANY):

We hereby certify that the valuer(s) is/are suitably qualified and authorized to practice as a valuer; does not have a pecuniary interest, financial or otherwise, that could conflict with the proper valuation of the company (including the parties with whom the company is dealing, including the lender or selling agent, if any). The valuer(s) accept instructions to value the company only from the appointing authority or eligible instructing party.

We have no present or planned future interest in DIPNA PHARMACHEM LIMITED or its group companies, if any and the fee payable for this valuation is not contingent upon the value of shares reported herein.

6. DATE OF APPOINTMENT, VALUATION DATE AND DATE OF REPORT:

Date of appointment	24/02/2025
Relevant date	05/03/2025
Date of report	05/03/2025

7. INSPECTIONS AND/OR INVESTIGATIONS UNDERTAKEN

The Valuation of the Company is being done as on the Valuation Date considering the 90 Trading days (i.e., from 25th October, 2024 to 4th March, 2025) and 10 trading days (from 18th February, 2025 to 4th March, 2025) BSE Volume weighted average price and documents produced before us for the purpose of ascertaining the Independent fair value of equity shares of the Company.

We have relied on accuracy and completeness of all the information and explanations provided by the management. We have not carried out any due diligence or independent verification or validation to establish its accuracy or sufficiency. We have received representations from the management and have accordingly assessed the fair value of the company. We believe that given the nature of the valuation and the underlying reports made available to us, it is plausible to carry out such valuation.



8. SOURCES OF INFORMATION:

In the course of performing the valuation, we have relied on the following sources:

- i. Background documents and information on the company;
- ii. Volume weighted average price for a period of 90 Trading days (i.e., from 25th October, 2024 to 4th March, 2025) and 10 trading days (from 18th February, 2025 to 4th March, 2025) for the Equity Shares of the Company quoted on BSE and its average.
- iii. Audited Balance sheet as on 31st March 2024, 2023 and 2022
- iv. Verbal information and discussions with the management.
- v. Data/Information of other comparable companies from BSE Limited
- vi. Other related information from various sources
- vii. Information from BSE website and Ministry of Corporate Affairs (MCA) Website.
- viii. Provisional financials statement as on 30.09.2024

We have assumed and relied upon the truth, accuracy and completeness of the information, data and financial terms provided to us or used by us; we have assumed that the same are not misleading and do not assume or accept any liability or responsibility for any independent verification of such information or any independent technical valuation or appraisal of any of the assets, operations or liabilities of the Company.

9. RESTRICTIONS ON USE OF THE REPORT:

This Valuation Report has been issued on the specific request of the management for the Value of the Company as on 05/03/2025.

Specific Purpose:

Valuation analysis and its results are specific to the purpose of valuation as mentioned in the section “**Purpose of Valuation**”. It may not be relevant for any other purpose or entity. This Report is prepared exclusively for the above stated purpose and must not be copied, disclosed or circulated or referred to in correspondence or discussion with any other party. Neither this report nor its content may be used for any other purpose without our prior written consent.

Not an advice to buy or sell:

The analysis in this report is based on the information provided by the management and such information as is obtained from market sources. However, our report is not advising anybody to take a buy or sell decision, for which specific opinion may be required from experts.



10. CAVEATS, LIMITATIONS AND DISCLAIMERS:

Valuation date:

The valuation of the Company contained herein is not intended to represent at any time other than the date that is specifically stated in this report. We have no responsibility to update this report for events and circumstances occurring after the valuation date.

Reliance on information provided:

We have assumed and relied upon the truth, accuracy and completeness of the information, data and financial terms provided to us or used by us; we have assumed that the same are not misleading and do not assume or accept any liability or responsibility for any independent verification of such information or any independent technical valuation or appraisal of any of the assets, operations or liabilities of the Company. In the course of the valuation exercise, we have obtained both oral and written data, including market, technical, operational and financial information. We have evaluated such information through a broad comparative analysis and enquiry.

Actual results may differ:

The assumptions used in their preparation, as we have been explained, are based on the management's present expectation of both – the most likely set of future business events and the management's course of action related to them. Wherever we have not received details information from the management, we have used our assessment of value based on experiences and circumstances of the case. It is usually the case that some events and circumstances do not occur as expected or are not anticipated.

Questions or appearances:

Our engagement is limited to preparing the report to be submitted to the management. We shall not be liable to provide any evidence for any matters stated in the report nor shall we be liable or responsible to provide any explanation or written statement for any assumption, information, methodology or any other matter pertaining to the report.

Complete report:

This report shall at all times be read and interpreted in full, no part of it shall be read independently for any reason whatsoever.

11. VALUATION: PROCEDURES AND FACTORS:

The valuation exercise is aimed at the assessment of the Fair Value of the company. We are required to arrive at the above valuations based on internationally accepted valuation practices.

As per **RICS appraisal Manual**, the Fair Value (FV) is defined as *'The price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.'*



Ind AS (113) as well as IFRS 13 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

Approach and Methodology

Valuation is not an exact science and is dependent on various factors such as specific nature of business, economic life cycle in which the industry and company is operating, past financial performance of the business, future growth potential of the business, business model, management of the company, relevance of technology in the business model, liquidity of equity and much more. The results of the valuation exercise may vary significantly depending on the basis used, the specific circumstances and the judgement of the valuer. In respect of going concerns, certain valuation techniques have evolved over time and are commonly in vogue.

IVS 105 read with IVS 200 specifies that generally the following three approaches for valuation of business/business ownership interest are used:

- I. Cost Approach - Net Asset Value (NAV)
- II. Income Approach
- III. Market Approach.

I. Cost Approach - Net Asset Value (NAV)

The value under Cost Approach is determined based on the underlying value of assets which would be on book value basis, replacement cost basis or on the basis of Realizable value. The Net Assets Method represents the value with reference to historical cost of assets owned by the company and the attached liabilities on particular date. Net asset will be calculated starting from the total assets of the company and deducting there from all debts, borrowing and liabilities, including current and Likely contingent Liability and preference capital if any. In other words, it should represent true net worth of business after providing for all outside present and potential liabilities. In the case of companies, the net assets value calculated from assets side of the balance sheet in the above manner will be crossed checked with equity share capital plus free reserve and surplus, less likely contingent liabilities.

We have considered the above approach as the said method derives the value with reference to historical cost of assets owned by the company and the attached liabilities on particular date as detailed in *Annexure-“1”*.

II. Income Approach

Under income approach there are mainly two methods

1. Discounted Cash Flows (DCF) method
2. Profit-earning capacity value method



1. Discounted Cash Flows (DCF) method

Under DCF method, business is valued by converting maintainable or future amount of cash flows to a single current amount either through discounting or capitalization. DCF method seeks to arrive at the value of the business based on its future cash flows generating capability and the risks associated with the said cash flows. Free Cash Flow to Firm (FCFF) represents the cash flows available for distribution to both the owners and other creditors of the business. Risk-adjusted discount rate or Weighted Average Cost of Capital (WACC) is applied to free cash flows in the explicit period and that in perpetuity. Adjustments pertaining to debt, surplus/non-operating assets including investments, cash & bank balances and contingent assets/liabilities and other liabilities, as relevant, are required to be made in order to arrive at the value for equity shareholders. The total value for the equity shareholders so arrived is then to be divided by the number of equity shares to arrive at the value per equity share of the company.

2. Profit-earning capacity value method

Under profit-earning capacity value method, the profit-earning capacity value will be calculated by capitalising the average of the after-tax profits at the following rates;

I. 15% in the case of manufacturing companies.

II. 20% in the case of trading companies.

III. 17.5% in the case of “intermediate companies”, that is to say, companies whose turnover from trading activity is more than 40%, but less than 60% of their total turnover.

The crux of estimating the profit-earning capacity value lies in the assessment of the future maintainable earnings of the business. While the past trends in profits and profitability would serve as a guide, it should not be overlooked that the valuation is for the future and that it is the future maintainable stream of earnings that is of greater significance in the process of valuation. All relevant factors that have a bearing on the future maintainable earnings of the business must, therefore, be given due consideration.

The detailed price working under this method is marked as **Annexure- "2"**

III. **Market Approach:**

Market approach is a valuation approach that uses prices and other relevant information generated by market transactions involving identical or comparable (i.e., similar) assets, liabilities or a group of assets and liabilities, such as a business.

The following valuation methods are commonly used under the market approach:

- a) Market Price Method;
- b) Comparable Companies Multiple (CCM) Method; and
- c) Comparable Transaction Multiple (CTM) Method;



a) Market Price Method

Under this method a valuer shall consider the traded price observed over a reasonable period while valuing assets which are traded in the active market. A valuer shall also consider the market where the trading volume of asset is the highest when such asset is traded in more than one active market. A valuer shall also consider the market where the trading volume of asset is the highest when such asset is traded in more than one active market.

The Equity Shares of Company are listed on BSE for a period of more than 90 trading days as on the relevant date i.e. March 05, 2025 and are frequently traded in accordance with SEBI ICDR Regulations.

In case of “frequently traded shares (Regulation 164(1) of the SEBI ICDR Regulations:

If the equity shares of the Company have been listed on a recognised stock exchange for a period of 90 trading days or more as on the relevant date, the price of the equity shares to be allotted pursuant to the preferential issue shall be not less than higher of the following;

- a. the 90 trading days’ volume weighted average price of the related equity shares quoted on the recognised stock exchange preceding the relevant date; or
- b. the 10 trading days’ volume weighted average prices of the related equity shares quoted on a recognised stock exchange preceding the relevant date.

Provided that if the Articles of Association of the issuer provide for a method of determination which results in a floor price higher than that determined under these regulations, then the same shall be considered as the floor price for equity shares to be allotted pursuant to the preferential issue.

Articles of Association of the Company do not provide for any particular method of determination which results in a floor price higher than that determined under SEBI ICDR Regulations.

Accordingly, we have determined value of equity share of the company as prescribed under the above regulations for market approach.

We have considered this method for valuation of equity shares of company as detailed in **Annexure- “3”**.

b) Comparable Companies Multiple (CCM) Method

Comparable Companies Multiple Method, also known as Guideline Public Company Method, involves valuing an asset based on market multiples derived from prices of market comparable traded on active market. Under this method, the value of shares of the subject company is determined on the basis of multiples derived from valuations of comparable companies. Relevant multiples need to be chosen carefully and adjusted for differences between the circumstances. The CCM Method arrives at the value of the company by using multiples derived from valuations of comparable companies, as manifest through stock market valuations of listed companies. This valuation is based in the principle that market



valuations, taking place between informed buyers and sellers, incorporate all factors relevant to valuation.

c) Comparable Transaction Multiple (CTM) Method

Comparable Transaction Multiple Method, also known as ‘Guideline Transaction Method’ involves valuing an asset based on transaction multiples derived from prices paid in transactions of asset to be valued /market comparable (comparable transactions). We have therefore not considered CTM method for valuation due to non-availability of similar comparable transaction.

12. VALUATION ANALYSIS:

The value per equity share of the company are based on the various approaches/methods explained herein earlier and various qualitative factors relevant to each company and the business dynamics and growth potential of the business of the Companies, having regard to information base, key underlying assumptions and limitations. We have applied all the methods discussed above, as considered appropriate, i.e. Cost Approach method, Profit earning capacity value Method and Market Price Method and for determining value per share of the company.

In light of the above and on consideration of all the relevant factors and circumstances as discussed and outlined herein above referred to earlier in this report for the proposed transaction, We recommend the fair value of equity shares of DPL at **INR 13.02 (Thirteen Rupee two paisa only per equity share).**

In terms of first Proviso to the Sub-Regulation 1 of Regulation 166A and Regulation 164 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and by using the Valuation Parameters, the following is the Valuation Analysis of Equity Shares of the Company.

Sr. No.	Valuation Parameters	Value per Equity Share (in Rupees)
1.	Net Asset Value Method	15.74
2.	Profit Earning Capacity Value Method	0.09
3.	Market Price Method	12.84

For, detailed working calculation of Value of Equity Share, please refer;

- Annexure 1 - For Net Asset Value Method
- Annexure 2 - For Profit Earning Capacity Value Method
- Annexure 3 - For Market Price Method



For arriving at the value of per equity share of DPL and considering valuation inputs available for determining valuation under NAV method, Profit Earning Capacity Value Method and Market Price Method we have applied weights to arrive at the value per equity share of DPL. (i.e. 40% weightage to Market Price method as equity shares of the company are frequently traded and this method depicts accurately reflects the intrinsic value of the share. Further, 10% weightage is given to PECV method as this method provides fair value of equity share considering an estimate of future maintainable profits and also we have given 50% weightage to Net Asset Value Method as the value derived from this method resembles true net worth of business after providing for all outside present and potential liabilities.

Sr. No.	Method	Valuer per equity share (in Rs.)(A)	Weights (B)	Weighted (C=A*B)
(a)	Net Asset Value Method	15.74	50%	7.87
(b)	Profit Earning Capacity Value Method	0.09	10%	0.01
(c)	Market Price Method	12.84	40%	5.14
TOTAL(D)			100%	13.02
Floor price (In Rupees)				13.02

13. CONCLUSION:

In the ultimate analysis, valuation will have to involve the exercise of judicious discretion and judgment taking into account all the relevant factors. There will always be several factors, e.g. present and prospective competition, yield on comparable securities and market sentiments etc. which are not evident from the face of the documents available with me but which will strongly influence the worth of a Shares and Debentures.

In the light of the above and on consideration of all the relevant factors and circumstances as discussed and outlined in this report, I conclude that the Floor Price of the Equity Share of the Company having Face Value of Rupee 10.00 each in terms of first Proviso to the Sub-Regulation 1 of Regulation 166A of the SEBI ICDR Regulations and in terms of the Regulation 164 of the SEBI ICDR Regulations as at Relevant date **is INR 13.02 (Thirteen Rupee two paisa only per equity share).**

Further, as per second proviso to Regulation 166A of SEBI (ICDR) Regulations, 2018, if any proposed preferential issue is likely to result in a change in control of the issuer, the valuation report from the registered valuer shall also cover guidance on control premium, which shall be computed over and above the price determined in terms of the first proviso. Accordingly, in this proposed preferential issue it is being informed by the management of the company that there is no change in control of the issuer and therefore there is no requirement for covering control premium over the price determined hereinabove.



Annexure “1”

(i) Net Asset Value per share of DIPNA PHARMACHEM LIMITED

Particular	(30.09.2024) Amount in Rs.
LIABILITIES	
Share Capital	24,04,52,500
Reserve and Surplus	13,81,00,000
Long Term Borrowings	14,93,63,000
Short Term Provisions	57,80,000
Deferred tax liabilities	
Other current liabilities	26,14,000
Short-term Borrowings	2,12,55,000
Trade Payables	77,36,01,000
TOTAL	1,33,11,65,500
ASSETS	
Property, plant & equipment	3,27,000
Deferred tax assets	26,000
Other current assets	1,06,80,500
Trade Receivables	46,86,75,000
Cash and cash equivalents	2,01,000
Inventories	25,98,34,000
Short-term Loans and Advances	59,14,22,000
TOTAL	1,33,11,65,500
NET ASSET VALUE	37,85,52,500
No. of shares (Face value @10 Rs.)	2,40,45,250
Book value in Rs. (NET ASSET VALUE/No. of Shares)	15.74



Annexure- “2”
Profit Earning Capacity value (PECV)

For the year ended on:	Weight	PAT in lacs	Details
31-03-2024	4	1,08,53,000	43412000
31-03-2023	2	91,19,000	18238000
31-03-2022	4	1,16,68,691	46674764
Average Profit after Tax			10832476
No. of equity shares			24045250
Average EPS			0.45
Capitalisation rate of Industry @			20%
PECV based Equity Value per Share			0.09

Note: We are giving average to the financial year in accordance with PAT of respective year. Higher the PAT higher the weighted average vice versa.

Under profit-earning capacity value method, the profit-earning capacity value will be calculated by capitalising the average of the after-tax profits at the following rates;

- I. 15% in the case of manufacturing companies.
- II. 20% in the case of trading companies.
- III. 17.5% in the case of “intermediate companies”, that is to say, companies whose turnover from trading activity is more than 40%, but less than 60% of their total turnover.



ANNEXURE “3”:
Volume Weighted Average Price BSE “90 Trading days”

S. No.	Date	No. of Shares	Total Turnover (Rs.)
1	04-Mar-25	30000	376050
2	03-Mar-25	63000	800160
3	28-Feb-25	54000	680340
4	27-Feb-25	69000	853500
5	25-Feb-25	66000	770220
6	24-Feb-25	15000	179760
7	21-Feb-25	57000	668550
8	20-Feb-25	30000	364740
9	19-Feb-25	30000	360120
10	18-Feb-25	42000	524760
11	17-Feb-25	66000	847260
12	14-Feb-25	51000	693450
13	13-Feb-25	15000	209400
14	12-Feb-25	30000	426810
15	11-Feb-25	51000	746850
16	10-Feb-25	66000	985770
17	07-Feb-25	75000	1143120
18	06-Feb-25	87000	1369890
19	05-Feb-25	816000	12977910
20	04-Feb-25	228000	3576690
21	03-Feb-25	36000	534060
22	01-Feb-25	96000	1393410
23	31-Jan-25	48000	685500
24	30-Jan-25	186000	2548470
25	29-Jan-25	39000	557760
26	28-Jan-25	135000	1988280
27	27-Jan-25	141000	2172120
28	24-Jan-25	57000	848880
29	23-Jan-25	78000	1154340
30	22-Jan-25	96000	1455570
31	21-Jan-25	228000	3619080
32	20-Jan-25	84000	1277280
33	17-Jan-25	102000	1500600
34	16-Jan-25	57000	832110
35	15-Jan-25	99000	1453770
36	14-Jan-25	270000	4299660
37	13-Jan-25	168000	2615760
38	10-Jan-25	321000	4677000



S. No.	Date	No. of Shares	Total Turnover (Rs.)
39	09-Jan-25	318000	4584060
40	08-Jan-25	240000	3561210
41	07-Jan-25	552000	8870730
42	06-Jan-25	360000	5652000
43	03-Jan-25	594000	8683500
44	02-Jan-25	399000	5761500
45	01-Jan-25	3240000	47379930
46	31-Dec-24	4476000	64109040
47	30-Dec-24	342000	4480200
48	27-Dec-24	789000	9396990
49	26-Dec-24	1410000	15083310
50	24-Dec-24	1386000	12347010
51	23-Dec-24	42000	308760
52	20-Dec-24	42000	305760
53	19-Dec-24	39000	283410
54	18-Dec-24	48000	350130
55	17-Dec-24	21000	156960
56	16-Dec-24	15000	114960
57	13-Dec-24	12000	91680
58	12-Dec-24	9000	66870
59	11-Dec-24	78000	590040
60	10-Dec-24	99000	767910
61	09-Dec-24	78000	640080
62	06-Dec-24	111000	933870
63	05-Dec-24	255000	2149770
64	04-Dec-24	480000	3637080
65	03-Dec-24	21000	142320
66	02-Dec-24	66000	448650
67	29-Nov-24	57000	384570
68	28-Nov-24	48000	334200
69	27-Nov-24	27000	183540
70	26-Nov-24	21000	142920
71	25-Nov-24	30000	210870
72	22-Nov-24	12000	80880
73	21-Nov-24	54000	367380
74	19-Nov-24	117000	793860
75	18-Nov-24	45000	311280
76	14-Nov-24	69000	477720
77	13-Nov-24	105000	715170
78	12-Nov-24	444000	2964330
79	11-Nov-24	48000	347190



S. No.	Date	No. of Shares	Total Turnover (Rs.)
80	08-Nov-24	33000	244590
81	07-Nov-24	42000	315480
82	06-Nov-24	63000	459390
83	05-Nov-24	60000	436410
84	04-Nov-24	42000	306540
85	01-Nov-24	36000	265050
86	31-Oct-24	45000	326100
87	30-Oct-24	117000	838410
88	29-Oct-24	42000	300090
89	28-Oct-24	33000	237090
90	25-Oct-24	111000	800850
	Total	21405000	274910640
			12.84

Volume Weighted Average Price BSE "10 Trading days"

S. No.	Date	No. of Shares	Total Turnover (Rs.)
1	04-Mar-25	30000	376050
2	03-Mar-25	63000	800160
3	28-Feb-25	54000	680340
4	27-Feb-25	69000	853500
5	25-Feb-25	66000	770220
6	24-Feb-25	15000	179760
7	21-Feb-25	57000	668550
8	20-Feb-25	30000	364740
9	19-Feb-25	30000	360120
10	18-Feb-25	42000	524760
	Total	456000	5578200
			12.23

A	Average of 90 trading days VWAP	12.84
B	Average of 10 trading days VWAP	12.23
C	Applicable Minimum Price (Higher of the A or B)	12.84

